We are live on ! Find out more
MDNA

Medicenna Therapeutics Corp. Common Shares

Delisted

MDNA was delisted on the 1st of November, 2023.

31 hedge funds and large institutions have $22.9M invested in Medicenna Therapeutics Corp. Common Shares in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

333% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 3

111% more capital invested

Capital invested by funds: $10.8M → $22.9M (+$12.1M)

48% more funds holding

Funds holding: 2131 (+10)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

Holders
31
Holders Change
+10
Holders Change %
+47.62%
% of All Funds
0.54%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
5
Reduced
4
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$30K -$147K -36,200 -83%
BlackRock
27
BlackRock
New York
$24K
FDCDDQ
28
Federation des caisses Desjardins du Quebec
Quebec, Canada
$15.7K -$4.48K -1,100 -22%
Osaic Holdings
29
Osaic Holdings
Arizona
$9K +$8.14K +2,000 +1,136%
TRCT
30
Tower Research Capital (TRC)
New York
$4K +$4.22K +1,036 New
SCM
31
Soleus Capital Management
Connecticut
-$874K -186,799 Closed
Bank of America
32
Bank of America
North Carolina
-$111K -23,619 Closed
KPF
33
K2 Principal Fund
Ontario, Canada
-$60K -10,167 Closed

MDNA Hedge Fund Activity: Q1 2021 in Review

31 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q1 2021, worth a combined $22.9M — up 111% from $10.8M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new MDNA positions and 3 closed out — a net gain of 10 holders — while 5 added to existing stakes and 4 trimmed.

The largest buyer was Board of Trustees of The Leland Stanford Junior University, opening a new position worth an estimated $3.92M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $874K sold.

  • 31 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q1 2021, up from 21 in Q4 2020.
  • Funds reported $22.9M of Medicenna Therapeutics Corp. Common Shares stock for Q1 2021, up 111% quarter-over-quarter.
  • 13 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q1 2021 and 3 closed out, a net change of +10 holders.
  • The largest Medicenna Therapeutics Corp. Common Shares buyer in Q1 2021 was Board of Trustees of The Leland Stanford Junior University, an estimated $3.92M added.
  • The largest Medicenna Therapeutics Corp. Common Shares seller in Q1 2021 was Soleus Capital Management, an estimated $874K sold.

Based on aggregated 13F filings for Q1 2021.